Indeed, trifluoperazine (TFP), a FDA-approved anti-psychotic drug, impeded proliferation, invasion, and motility of glioblastoma cells in vitro and in vivo by eliciting Ca2+ release from the ER through IP3R1 and IP3R2 channels, while IP3R3 channels were dispensable for TFP-induced Ca2+ mobilization. The gene discussed is ITPR3; the disease is glioblastoma.